H.B. Fuller (FUL) Q1 2026 earnings review
Profit Upgrades Mask Sharp Volume Deterioration
H.B. Fuller delivered a profitable first quarter, beating expectations and raising its full-year earnings guidance despite a deteriorating top line. While Adjusted EPS grew 6% and Adjusted EBITDA margin expanded 90 basis points to 15.4%, underlying sales quality flashed red. Organic volume collapsed 7.2% year-over-year—a severe deceleration from the 2.5% decline in Q4. Management successfully executed 'self-help' measures, utilizing the Quantum Leap restructuring program and raw material optimization to expand margins. However, with new supply chain disruptions in the Middle East prompting a fresh 'strategic pricing initiative,' the company is increasingly relying on price and cost-cutting to outrun volume contraction.
🐂 Bull Case
Despite a massive volume drop, Adjusted Gross Margin expanded 170 basis points to 31.3%. The company's restructuring and sourcing discipline continues to insulate the bottom line from demand shocks.
Management signaled confidence by raising FY26 Adjusted EBITDA guidance to $645-$675M. This suggests they expect the volume bleeding to stabilize or that cost savings are structurally permanent.
🐻 Bear Case
A 7.2% organic volume decline is severe. If demand destruction continues to accelerate, cost savings will eventually fail to offset the top-line erosion.
Management announced a new strategic pricing initiative to combat Middle East supply chain costs. Forcing price increases into a market that is already rejecting 7% of volumes carries significant elasticity risks.
⚖️ Verdict: ⚪
Neutral. The earnings quality is heavily mixed. H.B. Fuller's ability to wring out margin expansion and raise guidance is commendable, but an enterprise cannot shrink its volumes indefinitely and expect to sustain long-term value creation.
Key Themes
Volume Contraction is Accelerating
The most glaring concern in Q1 is the trajectory of organic volume. After posting a 1.7% gain in 25Q1, volume has decelerated in every consecutive quarter, culminating in a sudden 7.2% drop this quarter. This drove a total organic revenue decline of 6.6%. The company is struggling to find organic growth across any of its major end markets.
Margin Expansion Engine Remains Intact
Stable. While the top line faltered, profitability metrics continued to climb. Adjusted Gross Profit margin hit 31.3%, up 170 basis points year-over-year. Management credited cost savings associated with the Quantum Leap restructuring program, targeted price management, and lower raw material costs. This 'self-help' strategy continues to be the primary investment thesis for the stock.
Middle East Disruption & Impending Price Hikes
A new macroeconomic headwind emerged, as CEO Celeste Mastin specifically cited geopolitical instability in the Middle East as a source of significant complexity and cost to global supply chains. To combat this, the company announced a new 'strategic pricing initiative.' Given the current extreme volume weakness, forcing additional price hikes risks alienating customers and exacerbating the volume bleed.
HHC Segment Plunges
Decelerating. The Hygiene, Health and Consumable Adhesives (HHC) segment—the company's largest—saw organic growth collapse to -10.1% year-over-year. While segment Adjusted EBITDA grew slightly (+2.4%), this massive top-line erosion indicates either significant market share loss, intense destocking, or aggressive portfolio pruning that is hurting scale.
Other KPIs
Stable. The ratio held flat compared to the end of FY25 (3.1x) and improved from 3.5x a year ago. Total net debt sits at $1.97 billion, down $106 million YoY, demonstrating disciplined cash management despite the volume challenges.
While reported SG&A rose 4% year-over-year, management noted that adjusting for the impact of acquisitions and foreign exchange, SG&A was actually down slightly. This reflects stringent expense management critical to hitting their margin targets in a low-volume environment.
Net cash used in operating activities was -$4.0 million, a material improvement from the -$52.9 million used in the same quarter last year. This was primarily driven by higher net income and better working capital sequencing.
Guidance
Accelerating. Raised from the previous Q4 implied guidance of $630-$660 million. The new midpoint of $660M represents healthy growth compared to the $621M generated over the trailing twelve months, signaling confidence in sustained cost and pricing leverage.
Accelerating. Raised from the previous range of $4.35-$4.70. This outlook incorporates the benefit of higher operating income as well as lower shares outstanding resulting from recent buyback programs.
Reversing. This is a highly aggressive target given Q1 net revenue was down 2.3% and organic revenue was down 6.6%. To achieve 'mid-single-digit' growth for the full year, the company will need a massive acceleration in the remaining three quarters.
Accelerating. Represents sequential growth from Q1 ($119M) and year-over-year growth from 25Q2 ($166M). This implies robust margin defense even as Q2 revenue is only guided to be 'up low-single digits'.
Key Questions
Volume Collapse Anatomy
Organic volume declined 7.2% this quarter. How much of this decline is deliberate portfolio optimization (exiting low-margin business) versus underlying end-market demand destruction or competitive share loss?
Revenue Guidance Bridge
You are guiding for full-year net revenue to be up mid-single digits despite a 2.3% decline in Q1. What specific end-markets or internal catalysts give you confidence in such a sharp reversal for the remainder of the year?
Pricing Elasticity Risks
With volumes already down heavily, how are customers responding to the newly announced 'strategic pricing initiative' linked to Middle East supply chain disruptions? Are you modeling further volume attrition as a consequence of these price hikes?